NCT01689129 - Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

April 30, 2014

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Insulin glargine new formulation (HOE901)

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

Insulin glargine (HOE901) (Lantus)

Pharmaceutical form: solution Route of administration: subcutaneous

Trial Locations (22)

Investigational Site Number 392119, Amagasaki-Shi

Investigational Site Number 392106, Chūōku

Investigational Site Number 392107, Chūōku

Investigational Site Number 392110, Ebina-Shi

Investigational Site Number 392115, Higashiosaka-Shi

Investigational Site Number 392117, Izumisano

Investigational Site Number 392109, Kamakura-Shi

Investigational Site Number 392101, Koriyama-Shi

Investigational Site Number 392121, Kurashiki-Shi

Investigational Site Number 392112, Nagoya

Investigational Site Number 392120, Nishinomiya-Shi

Investigational Site Number 392113, Osaka

Investigational Site Number 392116, Osaka

Investigational Site Number 392118, Osaka

Investigational Site Number 392104, Shinjuku-Ku

Investigational Site Number 392105, Shinjuku-Ku

Investigational Site Number 392111, Shizuoka

Investigational Site Number 392114, Takatsuki-Shi

Investigational Site Number 392122, Tokushima

Investigational Site Number 392103, Tomioka-Shi

Investigational Site Number 392102, Ushiku-Shi

Investigational Site Number 392108, Yokohama